| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ST3GAL2 |
| Uniprot No | Q16842 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-350 aa |
| 活性数据 | MKCSLRVWFLSVAFLLVFIMSLLFTYSHHSMATLPYLDSGALDGTHRVKLVPGYAGLQRLSKERLSGKSCACRRCMGDAGASDWFDSHFDGNISPVWTRENMDLPPDVQRWWMMLQPQFKSHNTNEVLEKLFQIVPGENPYRFRDPHQCRRCAVVGNSGNLRGSGYGQDVDGHNFIMRMNQAPTVGFEQDVGSRTTHHFMYPESAKNLPANVSFVLVPFKVLDLLWIASALSTGQIRFTYAPVKSFLRVDKEKVQIYNPAFFKYIHDRWTEHHGRYPSTGMLVLFFALHVCDEVNVYGFGADSRGNWHHYWENNRYAGEFRKTGVHDADFEAHIIDMLAKASKIEVYRGN |
| 分子量 | 64.24 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ST3GAL2蛋白的3篇参考文献示例(注：文献为虚拟构造，仅作格式参考)：
1. **文献名称**：*ST3GAL2-mediated glycosylation promotes breast cancer metastasis*
**作者**：Zhang Y, et al.
**摘要**：研究揭示了ST3GAL2通过α2.3-唾液酸化修饰整合素β1.增强乳腺癌细胞侵袭能力，重组蛋白实验证实其酶活性促进肿瘤转移。
2. **文献名称**：*Recombinant human ST3GAL2 expression in CHO cells and its role in neuronal differentiation*
**作者**：Lee H, et al.
**摘要**：报道在CHO细胞中高效表达重组人ST3GAL2.并证明其催化生成的唾液酸化结构通过调节神经生长因子受体促进神经元分化。
3. **文献名称**：*Structural analysis of ST3GAL2 reveals substrate specificity determinants*
**作者**：Wang X, et al.
**摘要**：解析重组人ST3GAL2蛋白的晶体结构，阐明其底物结合域的关键氨基酸残基，为设计特异性抑制剂提供结构基础。
(以上文献为示例，实际需通过PubMed/Google Scholar等平台检索确认)
ST3GAL2 is a key enzyme in mammalian glycosylation, belonging to the ST3 β-galactoside α-2.3-sialyltransferase family. It catalyzes the transfer of sialic acid from CMP-sialic acid to terminal galactose residues on glycoproteins and glycolipids, forming α-2.3 linkages. This post-translational modification, known as sialylation, plays critical roles in cell-cell interactions, immune response modulation, and pathogen recognition. The ST3GAL2 gene is located on human chromosome 16q22 and is expressed in various tissues, with particularly high activity in the brain, pancreas, and placenta.
Recombinant human ST3GAL2 protein is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper folding and glycosylation patterns. Its enzymatic activity is calcium-dependent and occurs primarily in the Golgi apparatus. Researchers utilize this recombinant protein to study sialylation's impact on cellular processes such as cancer metastasis (through selectin ligand modification), neuronal development (affecting synaptic plasticity), and host-pathogen interactions (modulating viral receptor binding).
Aberrant ST3GAL2 expression has been associated with several diseases, including Alzheimer's (through amyloid-β sialylation), glioblastoma (affecting EGFR signaling), and influenza susceptibility. Pharmaceutical interest focuses on developing ST3GAL2 inhibitors for cancer immunotherapy and inflammation control. Structural studies of the recombinant protein have revealed conserved sialylmotif regions critical for substrate recognition, providing targets for rational drug design.
×
